Category: Federal Forum Posters
Purpose: Quarterly paliperidone palmitate extended-release injection represents the first long-acting injectable antipsychotic with a three-month dosing interval. Although promising data exists for the benefit of quarterly paliperidone palmitate long-acting injectable in patients with schizophrenia, there still remains a paucity of data regarding the clinical outcomes and side effects in patients who transitioned from one-month paliperidone palmitate to quarterly paliperidone palmitate. The purpose of this quality improvement study is to evaluate the clinical response and emergence of adverse effects correlated to the use of quarterly paliperidone palmitate in patients at a Veterans Affairs Healthcare System previously stabilized on one-month paliperidone palmitate.
Methods: A retrospective chart review was conducted on five patients in a Veterans Affairs Healthcare System. Eligible patients must have been initiated or maintained on quarterly paliperidone palmitate between August 1, 2016 and July 31, 2018. Information was retrieved from the Veterans Affairs Computerized Patient Record System (CPRS). Patient specific information including height, weight, waist circumference, body mass index, medication allergies, blood pressure, pulse, abnormal involuntary movement scale scores, response to treatment and laboratory data including complete blood count, basic metabolic panel, hemoglobin A1c, lipid panel, and electrocardiogram was collected and analyzed for changes that potentially are attributed to the use of quarterly paliperidone palmitate. Medications initiated with quarterly paliperidone palmitate that were used to manage psychiatric symptoms or side effects were documented. After data collection, the information was analyzed to determine if patients have adequate treatment response to the quarterly long-acting paliperidone palmitate injection without significant side effects.
Results: not applicable
Conclusion: not applicable
Mallory Poskus– Doctor of Pharmacy Candidate, University of Rhode Island College of Pharmacy, Smithfield, RI